{"prompt": "['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', 'A secondary audit may be conducted by Quality Assurance designated by the Sponsor. The', 'Investigator will be informed if this is to take place and advised as to the nature of the audit.', 'Representatives of the US FDA and/or representatives of other regulatory authorities may also', 'conduct an inspection of the study at the investigative site. If informed of such an inspection, the', 'Investigator should notify the Sponsor immediately.', 'Every effort will be made to maintain the anonymity and confidentiality of subjects participating', 'in this clinical study. However, because of the investigational nature of this treatment, the', 'Investigator agrees to allow representatives of the Sponsor, its designated agents, and authorized', 'employees of the appropriate regulatory agencies to inspect the facilities used in this study and to', 'have direct access to inspect, for purposes of verification, the hospital or clinical records of all', 'subjects enrolled in this study. A statement to this effect should be included in the ICF.', '13 DATA MANAGEMENT', \"Data will be entered into a clinical database as specified in the CRO's Data Management Plan.\", 'Quality control and data validation procedures will be applied to ensure the validity and accuracy', 'of the clinical database. Data will be reviewed and checked for omissions, apparent errors, and', 'values requiring further clarification using computerized and manual procedures. Data queries', 'requiring clarification will be communicated to the investigational site for resolution. Only', 'authorized personnel will make corrections to the clinical database, and all corrections will be', 'documented in an audit trail.', 'The coding of an AE, medical history and concomitant medication terms will be performed by', 'the CRO vendor and reviewed and approved by the Sponsor. Concomitant medications will be', 'coded using the World Health Organization Drug Dictionary (WHODrug) and AE/medical', 'history/surgery/non-drug therapy terms will be coded using the Medical Dictionary for', 'Regulatory Activities (MedDRA).', '14 RETENTION OF RECORDS', 'No study documents at the study site should be destroyed without prior written agreement', \"between the Sponsor and the Investigator. All subjects' medical records, the Investigator's copy\", 'of the eCRF, other supporting data, records of drug dispensing and accountability, signed ICFs,', 'IRB/IEC correspondence, and correspondence with the Sponsor must be kept by the Investigator', 'for at least 2 years and or as required by the local law following the date of the last approval of a', 'marketing application in an ICH region (including the US) and until there are no pending or', 'contemplated marketing applications in any other ICH region. If an application is not filed or not', 'approved for the indication under study, all study-related files must be retained for at least 2', 'years following the date of discontinuation of the clinical development program for', 'teprotumumab and for a period in compliance with all federal, state and local regulations. The', 'Sponsor must be notified prior to the disposal of any study-related files. If the Investigator leaves', 'the practice or institution during the required retention period, it is important that arrangements', 'be made for continued record retention. In that event, the records generally will be retained at the', 'institution at which the study was conducted.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 109 of 118']['Horizon Pharma USA, Inc.', 'Teprotumumab (HZN-001) IND: 112952', 'Date: 31 January 2019', 'Protocol: HZNP-TEP-302', 'Version 3.0, incorporating Protocol Version 2.1 and Amendment 2', '15 PUBLICATION', 'To avoid disclosures that could jeopardize proprietary rights, the institution and/or the', 'Investigator agree to certain restrictions on publications (e.g., abstracts, speeches, posters,', 'manuscripts, and electronic communications) as detailed in the Clinical Trial Agreement.', '16 REFERENCES', 'RO 4858696/F01-01 (huMAb-IGF-1R): A 7-week intermittent intravenous toxicity,', 'toxicokinetic and immunogenicity study with RO4858696/F01-01 (huMAb-IGF1R) in', 'cynomolgus monkeys with an 8-week recovery period (Covance Study No. 6131-477, HLR', 'Study No. 08954). Roche Report No. 1016123. 31 October 2005.', 'Method validation bioanalytical report for analysis of RO4858696 in monkey serum by ELISA', '(Study No. 09009). Roche Report No. 1016528. 29 June 2005.', 'RO4858696-000-009 (IGF-1R): Single dose pharmacokinetic study of RO4858696 following', 'intravenous administration to monkeys (Covance Study No. 6131-471, Roche Study No. 08791).', 'Roche Report No. 1016690. 21 April 2005.', 'RO4858696/F01-01 (huMAb-IGF-1R): Hemolytic potential and blood compatibility study with', 'RO4858696/F01 01 (HuMAb IGF 1R) (Covance Study No. 6131-491, HLR Study No. 09302).', 'Roche Report No. 1018657. 10 October 2005.', 'RO4858696/F01-01 (huMAb-IGF-1R) cross reactivity study of RO4858696 with normal', 'cynomolgus monkey tissues (PAIStudy No. IM1202, HLR Study No. 09256). Roche Report No.', '1019358. 03 October 2005.', 'Cynomolgus monkey as IGF-1R cross reactive species for RO4858696. Roche Report No.', '1019598. 08 August 2005.', '13-day intravenous administration toxicity study in the cynomolgus monkey (Covance Study No.', '2135-005). Roche Report No. 1020097. 10 October 2005.', 'A 13-week toxicity and toxicokinetic study of RO4858696 administered once weekly by', 'intravenous injection to cynomolgus monkeys, with a 12-week tecovery period (CRL Study No.', 'AGD00022, HLR Study No. 09927). Roche Report No. 1023600. March 2008.', 'In vitro evaluation of the Influence of RO4858696 on human and cynomolgus monkey whole', 'blood hemolysis and plasma flocculation (PCS MTL Study No. 600237, Roche Study No.', '10218). Roche Report No. 1026030. 14 September 2007.', 'RO4858696-F03/F05-01: A single dose intravenous comparative pharmacokinetic and', 'pharmacodynamic study of RO4858696 administered to male cynomolgus monkeys (Study No.', '09722). Interim draft report. Roche Report No. 1026674. 2007.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF HORIZON PHARMA USA, INC', 'Page 110 of 118']\n\n###\n\n", "completion": "END"}